International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 6 (November-December 2025) Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 6
November-December 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Inclisiran in Atherosclerotic Cardiovascular Disease: A Systematic Review of Efficacy and Safety for Lipid Lowering and Risk Mitigation

Author(s) Mr. D.R.Lokesh Kumar, Dr. Leena Pavitha
Country India
Abstract Background:
Intensive lowering of low-density lipoprotein cholesterol reduces cardiovascular risk in patients with atherosclerotic cardiovascular disease. However, most patients do not achieve optimal LDL-C targets due to clinical inertia, side effects, and nonadherence. Inclisiran, a small interfering RNA targeting PCSK9 synthesis, offers a novel approach for lipid lowering.
Objective:
The objective of this study was to systematically review the efficacy and safety of Inclisiran for lipid management and cardiovascular risk reduction in patients with atherosclerotic cardiovascular disease (ASCVD).
Methods:
A comprehensive literature search of PubMed and Scopus was conducted for peer-reviewed articles published between January 2020 and December 2024. Randomized controlled trials and observational studies evaluating Inclisiran in ASCVD patients were included. Primary outcomes were changes in low-density lipoprotein cholesterol (LDL-C) and safety profile; secondary outcomes included cardiovascular event rates and adherence.
Results:
Out of 314 identified records, 20 studies met the inclusion criteria. Inclisiran consistently reduced LDL-C by 28–60% across diverse populations. The most common adverse event was mild injection-site reactions. A significant 32% reduction in myocardial infarction incidence was reported, but effects on stroke and major adverse cardiovascular events were not statistically significant. Long-term data support durable LDL-C lowering with continued therapy.
Conclusion:
Inclisiran is a safe and effective lipid-lowering agent that significantly reduces LDL-C and is well-tolerated. Its convenient biannual dosing may improve adherence. While the reduction in myocardial infarction risk is promising, further long-term studies are needed to confirm broader cardiovascular benefits.
Keywords Inclisiran, PCSK9 inhibitor, Atherosclerotic cardiovascular disease, LDL-C, Safety and Efficacy.
Field Medical / Pharmacy
Published In Volume 7, Issue 6, November-December 2025
Published On 2025-11-25
DOI https://doi.org/10.36948/ijfmr.2025.v07i06.56532
Short DOI https://doi.org/hbcnv8
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 5Cover Page Vol 7 Isu 4Cover Page Vol 7 Isu 3

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com